Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate
- PMID: 17251298
- PMCID: PMC1866102
- DOI: 10.1128/JVI.01544-06
Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate
Abstract
KD-247, a humanized monoclonal antibody to an epitope of gp120-V3 tip, has potent cross-neutralizing activity against subtype B primary human immunodeficiency virus type 1 (HIV-1) isolates. To assess how KD-247 escape mutants can be generated, we induced escape variants by exposing bulked primary R5 virus, MOKW, to increasing concentrations of KD-247 in vitro. In the presence of relatively low concentrations of KD-247, viruses with two amino acid mutations (R166K/D167N) in V2 expanded, and under high KD-247 pressure, a V3 tip substitution (P313L) emerged in addition to the V2 mutations. However, a virus with a V2 175P mutation dominated during passaging in the absence of KD-247. Using domain swapping analysis, we demonstrated that the V2 mutations and the P313L mutation in V3 contribute to partial and complete resistance phenotypes against KD-247, respectively. To identify the V2 mutation responsible for the resistance to KD-247, we constructed pseudoviruses with single or double amino acid mutations in V2 and measured their sensitivity to neutralization. Interestingly, the neutralization phenotypes were switched, so that amino acid residue 175 (Pro or Leu) located in the center of V2 was exchanged, indicating that the amino acid at position 175 has a crucial role, dramatically changing the Env oligomeric state on the membrane surface and affecting the neutralization phenotype against not only anti-V3 antibody but also recombinant soluble CD4. These data suggested that HIV-1 can escape from anti-V3 antibody attack by changing the conformation of the functional envelope oligomer by acquiring mutations in the V2 region in environments with relatively low antibody concentrations.
Figures









Similar articles
-
Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.J Gen Virol. 2010 May;91(Pt 5):1335-45. doi: 10.1099/vir.0.017426-0. Epub 2009 Dec 23. J Gen Virol. 2010. PMID: 20032207
-
Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.AIDS. 2006 Oct 24;20(16):2065-73. doi: 10.1097/01.aids.0000247587.31320.fe. AIDS. 2006. PMID: 17053352
-
Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.AIDS. 2011 Nov 28;25(18):2209-16. doi: 10.1097/QAD.0b013e32834bab68. AIDS. 2011. PMID: 21866041
-
[Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].Enferm Infecc Microbiol Clin. 2009 Nov;27(9):523-30. doi: 10.1016/j.eimc.2008.02.010. Epub 2009 May 1. Enferm Infecc Microbiol Clin. 2009. PMID: 19409660 Review. Spanish.
-
Structural studies of human HIV-1 V3 antibodies.Hum Antibodies. 2005;14(3-4):73-80. Hum Antibodies. 2005. PMID: 16720977 Review.
Cited by
-
Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Retrovirology. 2014 Sep 25;11:75. doi: 10.1186/s12977-014-0075-y. Retrovirology. 2014. PMID: 25287422 Free PMC article.
-
Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG.Retrovirology. 2021 Aug 21;18(1):23. doi: 10.1186/s12977-021-00568-y. Retrovirology. 2021. PMID: 34419098 Free PMC article.
-
The HIV-1 env protein: a coat of many colors.Curr HIV/AIDS Rep. 2012 Mar;9(1):52-63. doi: 10.1007/s11904-011-0107-3. Curr HIV/AIDS Rep. 2012. PMID: 22237899 Free PMC article. Review.
-
Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.J Virol. 2010 Aug;84(15):7558-68. doi: 10.1128/JVI.00227-10. Epub 2010 May 26. J Virol. 2010. PMID: 20504942 Free PMC article.
-
Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.J Virol. 2011 Oct;85(20):10730-40. doi: 10.1128/JVI.00365-11. Epub 2011 Aug 10. J Virol. 2011. PMID: 21835798 Free PMC article.
References
-
- Bouma, P., M. Leavitt, P. F. Zhang, I. A. Sidorov, D. S. Dimitrov, and G. V. Quinnan, Jr. 2003. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1. J. Virol. 77:8061-8071. - PMC - PubMed
-
- Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208. - PubMed
-
- Carotenuto, P., D. Looij, L. Keldermans, F. de Wolf, and J. Goudsmit. 1998. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12:1591-1600. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials